Lucchi L, Govoni S, Memo M, Missale C, Spano P F, Trabucchi M
Toxicol Lett. 1986 Sep;32(3):255-60. doi: 10.1016/0378-4274(86)90116-5.
The effect of chronic lead treatment on pituitary dopamine (DA) D2 receptors was studied by measuring (-)sulpiride-displaceable [3H]spiroperidol-binding and DA-inhibited adenylate cyclase. Receptor number was reduced in lead-exposed animals and bromocriptine was less able to inhibit cyclase activity in pituitary homogenates. In addition, the capacity of DA to inhibit the VIP-stimulated cAMP formation was decreased.